Fasenra shows benefit in acute asthma and COPD in Phase II trial
The results demonstrate the safety and efficacy of Fasenra in the treatment of acute eosinophilic exacerbations in asthma and COPD.
28 November 2024
28 November 2024
The results demonstrate the safety and efficacy of Fasenra in the treatment of acute eosinophilic exacerbations in asthma and COPD.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.